Biotech and medical business blog

Visit BioHealth Investor

BioHealth & Medical Analyst Calls (AZN, NVS, NVO, CRL, IVGN, APPY, TWTI)

Posted on June 24, 2008

BNP Paribas overseas has lowered ratings of AstraZeneca (NYSE: AZN) to Underperform from Neutral; and raised Novartis (NYSE: NVS) to Neutral from Underperform.Goldman Sachs has raised Novo Nordisk (NYSE: NVO) to Buy from Neutral; Charles River Laboratories (NYSE: CRL) downgraded to Neutral at Goldman Sachs.JPMorgan has raised its rating on Invitrogen (NASDAQ: IVGN) to Overweight [...]...

Original article link